Small Molecule Drug Discovery
We strive to push the boundaries of AI for drug discovery by continuously inventing and integrating innovations across machine learning, biology and chemistry.
Our first proprietary AI-designed drug started Investigational New Drug-enabling studies eight months after program initiation.
Cooperations with biopharma in AI-enabled drug discovery with a focus on Difficult-to-Drug molecular targets.
MindRank has successfully delivered an allosteric inhibitor PCC with Best-in-Class potential to a public traded biotech company.
A Scientific Driven Team
MindRank consists of over 30 scientists from top biopharma and global AI competition winners. The team has extensive successful experience of small molecule drugs R&D and technological innovations with AI. Some of the innovations were published in venues such as Nature Biomedical Engineering, Patterns (Cell Press).
The company's proprietary AI solution was nominated by Deep Pharma Intelligence as one of the "Top AI Breakthroughs in Biopharma from 2018 to 2020".